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Phenoxodiol is a novel isoflav-3-ene, currently undergoing clinical trials, that has a broad in vitro activity against a number of human
cancer cell lines. Phenoxodiol alone inhibited DU145 and PC3 in a dose- and time-dependent manner with IC50 values of 8±1 and
38±9mM, respectively. The combination of phenoxodiol and cisplatin was synergistic in DU145, and additive in PC3, as assessed by
the Chou–Talalay method. Carboplatin was also synergistic in combination with phenoxodiol in DU145 cells. The activity of the
phenoxodiol and cisplatin combination was confirmed in vivo using a DU145 xenograft model in nude mice. Pharmacokinetic data
from these mice suggest that the mechanism of synergy may occur through a pharmacodynamic mechanism. An intracellular cisplatin
accumulation assay showed a 35% (Po0.05) increase in the uptake of cisplatin when it was combined in a ratio of 1mM:5mM
phenoxodiol, resulting in a 300% (Po0.05) increase in DNA adducts. Taken together, our results suggest that phenoxodiol has
interesting properties that make combination therapy with cisplatin or carboplatin appealing.
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Hormone refractory prostate cancer carries a poor prognosis, with
an expected median survival of around 12 months in symptomatic
patients. Recently, docetaxel in combination with either predni-
sone or estramustine has been shown to improve survival when
compared with the combination of mitoxantrone and prednisone
in phase III trials (Petrylak et al, 2004; Tannock et al, 2004). In
these trials, the median survival in the control arm was only 16
months. Given that many men are unsuitable for chemo-
therapy, either because they are elderly or have comorbidities,
there is still a pressing need to evaluate better-tolerated and more
effective compounds and combinations for the treatment of this
disease.
Epidemiological studies suggest an inverse relationship between
isoflavone consumption and the risk of prostate cancer (Jacobsen
et al, 1998; Strom et al, 1999). A significant (70%) reduction in the
risk of prostate cancer was associated with the consumption of soy
milk (a rich source of dietary isoflavones) in a cohort of over
12000 Seventh Day Adventist men (Jacobsen et al, 1998). Although
there are, as yet, no randomised trials of isoflavones in the
treatment or prevention of prostate cancer, there is strong in vitro
evidence for the activity of a variety of isoflavones on hormone-
sensitive and -insensitive prostate cancer cell lines (Hempstock
et al, 1998; Mitchell et al, 2000; Hedlund et al, 2003) and in vivo in
rats (Risbridger et al, 2001). Isoflavones appear to have pleiotropic
effects on prostate cancer cells, including an ability to exert
hormonal influences.
Phenoxodiol is a synthetic isoflav-3-ene metabolite that is a
natural intermediate (dehydroequol, 7,40-dihydroxyisoflav-3-ene)
in the metabolism of daidzein to equol (Joannou et al, 1995). It is
cytotoxic in vitro (Phenoxodiol Investigators Brochure, 2000;
Mor et al, 2006) and in vivo in rats (Constantinou et al, 2003;
Mor et al, 2006). It may be capable of re-sensitising platinum- and
taxane-resistant ovarian cancer cells in vitro (Kamsteeg et al, 2003;
Sapi et al, 2004; Kluger et al, 2007) and appears to have
antiangiogenic (Gamble et al, 2006) and anti-inflammatory
properties (Widyarini et al, 2001). It has improved bioavailability
when compared with genistein (Kelly and Husband, 2003) and low
toxicity in clinical trials (Joshua et al, 2003; Choueiri et al, 2006a;
de Souza et al, 2006).
Phenoxodiol appears to create a ‘pro-death’ environment by
activating the caspase cascade through the upregulation of pro-
apoptotic Bax (Alvero et al, 2006). It inhibits c-FLIP, activating the
FAS apoptotic pathway, and causes the downregulation and
cleavage of XIAP (Kamsteeg et al, 2003; Kluger et al, 2007),
leading to further activation of the caspases (Straszewski-Chavez
et al, 2004). Phenoxodiol also causes cell cycle arrest at G1 due to a
loss of cdk2 activity by p53-independent induction of the cdk
inhibitor p21
WAF1/CIP1 (Aguero et al, 2005). Cell cycle interference
occurs through the inhibition of topoisomerase II (Constantinou
and Husband, 2002). The molecular target for growth inhibition by
phenoxodiol is unclear, but may involve tumour-associated NADH
oxidase (Yagiz et al, 2006).
Our aim was to determine the in vitro growth-inhibitory ability
of phenoxodiol against prostate cancer cells, and to identify
whether cisplatin could enhance these abilities, and investigate
whether intracellular cisplatin uptake was altered by phenoxodiol.
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Phenoxodiol was supplied by Novogen Research Pty Limited
(Sydney, NSW, Australia). Cisplatin and carboplatin were pur-
chased from Sigma Chemicals (St Louis, MO, USA). Cell culture
reagents and consumables were obtained from Sigma Chemicals or
Invitrogen (Mulgrave, VIC, Australia). All other chemicals not
otherwise specified were of the highest grade and were purchased
from local suppliers.
Cell culture
Growth of the human androgen-independent prostate cancer cell
lines DU145 and PC3, as well as HepG2 (hepatoma) and 786-0
(renal), was maintained in an atmosphere of 5% CO2 at 371C.
DU145 cells were cultured in MEM Eagle’s media, whereas PC3
cells were maintained in high-glucose RPMI-1640 media. All media
were supplemented with foetal calf serum (10% v/v), 10mM Hepes,
1.5gl
 1 sodium bicarbonate and penicillin–streptomycin–gluta-
mine (1% v/v). DU145 and PC3 cells were obtained from Professor
David Morris (Department of Surgery, St George Hospital, NSW,
Sydney, Australia).
Growth-inhibition experiments
Cells were plated in 96-well plates (Falcon; Becton Dickinson,
Lincoln Park, NJ, USA) at 3000 cells per well in culture medium
and incubated for 24h. Drug stock solutions were diluted in
culture medium and added (100ml per well) in triplicate to achieve
final concentrations ranging from 0.1 to 10mM phenoxodiol, 0.001
to 100mM cisplatin and 1 to 100mM carboplatin. Drugs were
investigated for their activity as single agents, and in various
combinations and concentrations. After incubation for 72h, cell
viability was measured by the sulphorhodamine B assay as
described earlier (Skehan et al, 1990). Growth inhibition was
expressed as % control (media alone and no drugs) and
quantitated by IC50 values. All experiments were repeated in
triplicate; results are shown as mean±s.e.m. Schedule dependency
of the phenoxodiol and cisplatin combination was also investigated
by exposing cells simultaneously to both drugs for 72h or
sequentially to phenoxodiol first for 2 or 24h followed by the
addition of cisplatin for a further 48h, or vice versa.
Chou–Talalay analysis for synergy
Methods for assessing synergy were used as described earlier (de
Souza et al, 1997). Briefly, Calcusyn (version 2.0), a Windows
s-
based computer program automating the multiple-drug-effect
analysis of Chou and Talalay, based on the median-effect principle
(Chou and Talalay, 1984), was used to calculate combined drug
effects. The combination index (CI) equation CI¼(D)1/
(Dx)1þ(D)2/(Dx)2 was then used to determine synergy, additivity
or antagonism. Data are expressed as CI±s.e.m. Combination
indices of o1, ¼1 and 41 represent synergy, additivity and
antagonism, respectively. Mutually non-exclusive CIs are shown
because these do not assume knowledge of the mechanism of
action of the drugs in combination.
Whole-cell platinum accumulation and DNA
platinum-binding studies
DU145 cells were treated with cisplatin alone and in combination
(1 and 10mM) with phenoxodiol at 5mM for 24h, harvested by
trypsin and then washed twice with ice-cold PBS. Samples for the
whole-cell analysis of platinum accumulation were lysed with
500ml of water and analysed for total protein content by the
biocinchonic acid protein assay kit (Sigma-Aldrich, Sydney, NSW,
Australia). Samples for measuring platinum DNA binding were
lysed in 100mM Tris HCl, 5mM EDTA, 0.2% SDS and 200mM NaCl,
with 100mg proteinase K per ml added immediately before use.
DNA was precipitated with ice-cold isopropanol and the sample
digested in 500ml TE (10mM Tris HCl (pH 7.5) and 0.1mM EDTA)
and shaken overnight at 371C. A total DNA measure was
performed by analysis at 260/280 OD. Experiments were repeated
in triplicate. Samples were diluted 1:5 with 0.1% nitric acid and
analysed for platinum content by inductively coupled plasma mass
spectrometry (ICP-MS) as described below. Platinum measures
were adjusted as relevant to per mg of protein and mg of DNA
before comparisons between treatment groups were made.
In vivo experiments
Male Nu-Nu Balb/c mice (15–20g) were obtained from the Animal
Resource Centre (Perth, WA, Australia), housed in sterile filter-
topped microisolation cages and maintained on sterile water and a
sterile isoflavone-free diet (Gordon’s Speciality Stockfeeds, Yan-
derra, NSW, Australia) ad libitum. Mice were monitored until a
bodyweight of 20–25g was reached. Xenografts were established
by the dual subcutaneous injection of 1 10
6 DU145 cells in
serum-free MEM and Matrigel (1:1) on each hind flank under
inhalation anaesthesia (induced with 5% isofluorane/95% oxygen
and maintained with 1–2% isofluorane). The xenografts were left
to grow until approximately 20mm
2 in size before mice were
randomised into four treatment groups (at least n¼6 per group):
vehicle only, cisplatin (1mgkg
 1), phenoxodiol (5mgkg
 1) and
cisplatin plus phenoxodiol (0.5 and 2.5mgkg
 1, respectively).
Cisplatin was prepared fresh each day, dissolved in 0.9% saline
(0.1mgml
 1), whereas stock phenoxodiol was prepared in 20%
hydroxypropyl b-cyclodextrin (5mgml
 1) solubilised at 1201C.
Phenoxodiol was diluted daily in 0.9% saline. Drugs were given
through the intraperitoneal route daily on days 1–5 and 8–12.
Doses of cisplatin and phenoxodiol were chosen to give plasma
concentrations that would approximate the concentrations used in
in vitro experiments from literature (Litterst and Magin, 1988) and
bioavailability data supplied by Novogen. Xenograft diameters
were measured daily with vernier callipers and volumes calculated
by the formula Volume¼Length Width
2/2. Toxicity of the drugs
was determined by inspection of mice and bodyweight analysis.
Derivation of drug doses used for in vivo experiments
Doses were halved for both drugs in the cisplatin/phenoxodiol
group to allow the demonstration of synergy, if present, as
described earlier (de Souza et al, 1997). Thus, if the combination
proved to be as or more effective than either agent alone at double
the dose of each agent in the combination, we could conclude that
the combination showed additive, or synergistic activity, respec-
tively. The evidence for this decision is based on the Chou–Talalay
equation:
CI ¼ðDcombÞ1=ðDaloneÞ1 þð DcombÞ2=ðDaloneÞ2
þ aðDcombÞ1ðDcombÞ2=ðDaloneÞ1ðDaloneÞ2
where (Dalone)1 is the dose of drug 1 alone required for a given
effect (fa), (Dcomb)1 is the dose of drug 1 in the combination
required for a given effect (fa), (Dalone)2 is the dose of drug 2
alone required for a given effect (fa), (Dcomb)2 is the dose of drug
2 in the combination required for a given effect (fa), CI is a
measure of the degree of synergy and a¼0 if the effects of the two
drugs are mutually exclusive.
Let (Dalone)1¼some concentration p,( D a l o n e ) 2 ¼some con-
centration q, (Dcomb)1¼0.5p and (Dcomb)2¼0.5q;t h e nC I¼0.5p/
pþ0.5q/5þa(0.5p)(0.5q)/pq¼0.5pq/pqþ0.5pq/pqþ0.25pq/pq. If
the term a¼0, which is likely given the different mechanisms of
action of cisplatin and phenoxodiol, then CI¼1, which is also the
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sdefinition of additivity. The advantage of this method is that it is
dose independent and does not rely on the arbitrary definition of
time to recurrence/regrowth of tumours in vivo, for which there is
no mathematical definition of synergy. As a result, only four
treatment arms are required (vehicle control, drug A single-agent
control, drug B single-agent control and 0.5 drug Aþ0.5 drug B
in combination) for in vivo studies to test synergy.
Whole-tissue platinum analysis
Total platinum in the plasma, kidney and tumours was analysed by
ICP-MS as described earlier (Screnci et al, 1998). Tissues were
prepared by nitric acid digestion overnight and for 2h at 901Ci na
closed container. Sample volume was adjusted to 10ml with MilliQ
and the platinum content analysed. Plasma (50ml) was diluted in
1.2ml lysis buffer before analysis by ICP-MS. Calibration was
against a platinum standard curve from 0.1 to 10000ngml
 1.
Individual weights of tumours and kidneys were also recorded.
Pharmacokinetics
Upon completion of the study, mice were killed at specified time
points after cisplatin dosing by cervical dislocation for pharma-
cokinetic analysis. Cardiac puncture was performed immediately
and blood was centrifuged at 2000g for 5min and the plasma
supernatant stored at  801C for cisplatin concentration measure-
ments. At the same specified time points, the xenograft, liver and
kidney tissue were also removed, washed in PBS (pH 7.6) and
stored at  801C. The data were analysed using two-way repeated
measures ANOVA performed using STATVIEW version V (Abacus
Concepts Inc., Berkley, CA, USA). Fisher’s post hoc tests were
performed on all significant data. Pharmacokinetic parameters
were determined using non-compartmental analysis. Total plati-
num adjusted for tissue weight was plotted against time of sample.
Cmax (maximum platinum concentration) and Tmax (time of
maximum platinum concentration) were measured and the area
under the concentration verus time curve (AUC) was calculated by
the trapezoid rule (GraphPad Prism v3.00 for Windows, San Diego,
CA, USA).
RESULTS
Growth inhibition by phenoxodiol
Phenoxodiol was active against DU145 and PC3, with IC50 values of
8±1 and 38±9mM, respectively (Figure 1). Cell-growth inhibition
of both cell lines was dependent on both duration of exposure and
concentration of phenoxodiol.
Synergy analysis by Chou–Talalay analysis
Cisplatin and phenoxodiol generally showed synergistic activity
against DU145 (Figure 2A) with CIs less than 1.0. Although there
were some combination ratios that suggested antagonism, these
occurred at the extremes of the dose–response curves. Phenox-
odiol and cisplatin combined in PC3 cells to produce a mixed
(synergistic, additive and antagonistic) effect that overall suggested
additivity at best (Figure 2B). Synergy was also noted with
carboplatin at all concentrations of phenoxodiol (0.1–20mM)
against DU145 (Figure 2C). Mostly synergy interactions were
found in other (HepG2 and 786-0) cell lines (data not shown).
Sequence of administration of the drugs was important. A 24-h
delay between the administration of cisplatin followed by
phenoxodiol significantly decreased the synergism measured
(Po0.05), resulting in an antagonistic combination (average CI
1.8±0.5 vs 0.8±0.15). A 2-h delay did not affect synergism
between phenoxodiol and cisplatin nor did administering phenoxo-
diol 24h before cisplatin (data not shown).
Cisplatin whole-cell accumulation and DNA binding
A greater than 300% increase (Po0.05) in platinum binding to
DNA was measured in DU145 cells following treatment with
1mM cisplatin and 5mM phenoxodiol compared with 1mM
cisplatin alone (Figure 3A). A 35% increase (Po0.05) in the
whole-cell accumulation of platinum was measured in DU145
cells at the same concentrations (Figure 3B). No significant
difference in whole-cell accumulation of platinum or DNA




 1) alone and the combination of phenox-
odiol (2.5mgkg
 1) and cisplatin (0.5mgkg
 1) inhibited
(Po0.01) the rate of absolute xenograft growth compared with
control (Figure 4A). There was no statistically significant
difference between cisplatin alone and the combination
arms. Toxicity of cisplatin was monitored by recording
weight loss. A statistically significant average 3.4±0.3% loss of
weight was recorded for mice treated with cisplatin alone
(Po0.01), compared with other arms (Figure 4B). Mice in the
phenoxodiol and cisplatin group had less weight loss (Po0.01)
compared with the cisplatin alone group. No mice were
removed from treatment groups because of excessive weight loss
(410% bodyweight). There was no difference between mice in the
control and phenoxodiol groups, in which weight gain was
observed in the mice.
Cisplatin pharmacokinetics
Phenoxodiol did not appear to affect cisplatin plasma pharmaco-
kinetics. Tmax was rapid and occurred at 25min for both cisplatin
alone and the cisplatin–phenoxodiol combination. The Cmax for
the combination of cisplatin (0.5mgml
 1) with phenoxodiol
(2.5mgml
 1) was 782±115ngml
 1 (Figure 5). This was about
75% of the Cmax of cisplatin alone at twice the concentration
(1mgml
 1) (1041±21ngml
 1). The plasma AUC of cisplatin
dosed at 0.5mgml
 1 was approximately half that of the 1mgml
–1
group (21950ngml
 1 h at 0.5mgml
 1 in combination with
phenoxodiol vs 40740ngml
 1 h at 1mgml
 1 alone).
In kidney and tumour tissue, there was also no apparent
difference in circulating levels of free platinum, with measured
AUC for cisplatin at 0.5mgml
 1 in combination with phenoxodiol
approximately half the AUC of cisplatin 1mgml
 1 alone (2914























Figure 1 Cell viability curve following 72h of exposure to 0.1–100mM
phenoxodiol in ’ PC3 and m DU145 cells. Dashed line marks IC50.
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sconcentration time and 4294 concentration time for the kidney
and 812.4 concentration time and 1861 concentration time for
the tumour respectively, data not shown).
DISCUSSION
The novel isoflavone, phenoxodiol, has promising in vitro activity
against the prostate cancer cell lines DU145 and PC3, with DU145
being more sensitive than PC3. Complete inhibition of DU145 was
achieved, whereas only 60% inhibition of PC3 could be achieved at
the maximum solubility of phenoxodiol. Differences in sensitivity
may be due to phenotypic or genetic differences between the cell
lines but may also be dependent on the ability of phenoxodiol to
enhance apoptosis induction. For example, PC3 cells express more
Bcl-2 than DU145 (Skjoth and Issinger, 2006), and this may explain
its relative resistance to treatment.
Our data show that the combination of phenoxodiol is highly
synergistic with cisplatin against DU145 in vitro (Figure 2A).





































































Figure 2 Combination indices (CI, mutually non-exclusive) for cisplatin
and phenoxodiol in (A) DU145 and (B) PC3 prostate cancer cells, and (C)
carboplatin and phenoxodiol in DU145. CIo1 denotes synergism, CI¼1
additivity and CI41 antagonism. Combination indices 43 are not shown.
Phenoxodiol concentrations in (A), (B) and (C) are as follows: ’ 0.1mM,
m 1mM, . 3mM, ~ 5mM, K 7mM, * 10mM and & 20mM. All cells were
exposed to simultaneous drug combinations for 72h. The horizontal
dashed line highlights CI¼1.
No drug
Phenoxodiol  5 M
Cis 1 M
















































































Figure 3 Comparison of (A) cisplatin DNA adducts, measured as the
concentration of platinum bound to the DNA (pg platinum per mg DNA)
and (B) whole-cell platinum accumulation, recorded as the measure of
platinum present in the whole-cell sample (pg platinum per mg protein)
following exposure to no drug (control), phenoxodiol (5mM), cisplatin (Cis)
(1mM) or cisplatin (Cis) 1(mM) in combination with phenoxodiol (5mM).
Data shown are average level±s.e.m., *Po0.05.
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sChou–Talalay analysis of the combination shows a degree of
synergy consistent with that noted when other isoflavones are
combined with cisplatin (Bible and Kaufmann, 1997; Khoshyomn
et al, 2000), suggesting that this may be a class effect. Phenoxodiol
was also synergistic with carboplatin, perhaps not surprisingly,
given its similar mechanism of action to cisplatin. In our hands,
synergism between phenoxodiol and cisplatin is schedule
dependent, with the optimal schedule appearing to be the co-
administration of phenoxodiol and cisplatin, or at least
phenoxodiol before cisplatin. This is consistent with the finding
that cisplatin reduces cyclin D1 (Skjoth and Issinger, 2006),
thereby inhibiting cell cycle progression and reducing the number
of actively dividing cells available for phenoxodiol-induced
apoptosis.
We speculate that phenoxodiol may interact with cisplatin in a
number of ways to produce synergy in DU145 cells. DU145 cells
overexpress c-FLIP short, which may in part contribute to their
chemoresistance (Hyer et al, 2002), and the inhibition of c-FLIP by
phenoxodiol has been shown in ovarian cancer cells (Kamsteeg
et al, 2003). Phenoxodiol also induces Bax transcription (Hutson
et al, 2003), and could therefore potentiate the sensitivity of DU145
to cisplatin (Skjoth and Issinger, 2006) as transfection of Bax in
DU145 cells (naturally deficient in Bax) has been shown to
significantly enhance apoptosis to a variety of chemotherapy
agents including cisplatin (Honda et al, 2002). Modulation of
sphingosine-1-phosphate by phenoxodiol (Choueiri et al, 2006b)
may also directly alter cisplatin sensitivity. Finally, p38 induction
and an intact PTEN/Akt pathway has been suggested as the
mechanism for increased apoptosis in DU145 cells, relative to PC3,
induced by cisplatin (Skjoth and Issinger, 2006).
The in vivo data are consistent with, though not strongly
supportive of, our conclusions regarding the combination of
phenoxodiol and cisplatin. Given that mice were treated with
combination cisplatin/phenoxodiol at half-doses in the single-
agent control arms, we can conclude that the combination is
additive if the tumour growth curves matched, provided they were
better than the negative control (vehicle only) mice, as discussed in
Materials and Methods. Indeed, though the combination was better
than single-agent phenoxodiol, it was no better than cisplatin
alone, suggesting additivity in this xenograft experiment. The
findings in our nude mice studies also support the notion that
reducing the dose of both drugs and relying on their synergistic
activity can not only maintain growth inhibition, but also reduce
toxicity, as shown in the bodyweight curves. Further, this occurred
at plasma concentrations approximately 15 times less than those
found in human studies (van Hennik et al, 1987).
Though there was no apparent pharmacokinetic interaction
between phenoxodiol and cisplatin in our in vivo experiment, we
hypothesised that a pharmacodynamic interaction could not be
ruled out. Data from DNA-binding assays seem to support this
hypothesis. Phenoxodiol is not only synergistic with cisplatin in
cisplatin-sensitive cell lines but also re-sensitises cisplatin- and
carboplatin-resistant cell lines and tumours to the platinum agents
(Mor et al, 2006). This also occurs with the isoflavone genistein as
well as phenoxodiol’s parent compound, diadzein (Gercel-Taylor
et al, 2004). The mechanism of synergy between genistein and
cisplatin is thought to be due to an increased accumulation of
cisplatin within tumour cells as cisplatin accumulation of up to
83% occurs in sensitive ovarian cancer lines and 43% in resistant
lines (Marveti and Andrews, 1996). Although cisplatin is not
commonly used for the treatment of prostate cancer, we had earlier
determined that the combination of docetaxel and phenoxodiol
was only additive (unpublished), and we wished to pursue the
potentially synergistic combination. Further, platins may be of
renewed interest for this disease (Oh et al, 2007) in view of
the development of satraplatin (Kelland, 2000; Petrylak, 2007;
Wosikowski et al, 2007).
In conclusion, the combination of cisplatin or carboplatin with
phenoxodiol has synergistic activity in DU145 prostate cancer cells
and HepG2 hepatoma cells, and probably overall additivity in
786-0 renal cancer cells and PC3 cells. The synergy seen between






































































Figure 4 DU145 xenograft tumour volumes (mm
3)( A) and nude mice
% bodyweight changes (B) recorded over a 12-day treatment period for
the four treatment groups: m control, . phenoxodiol alone (5mgkg
 1),
~ cisplatin alone (1mgkg
 1) and K the combination of cisplatin
(0.5mgkg
 1) and phenoxodiol (2.5mgkg
 1). **A statistically significant
difference (Po0.01) for the cisplatin arm and the combination arm
compared with control; only statistically significant differences are shown
(see Results).
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Figure 5 Nude mouse plasma cisplatin concentration–time curves for
E cisplatin alone (1mgkg
 1) and K the combination of cisplatin
(0.5mgkg
 1) and phenoxodiol (2.5mgkg
 1). Halving the cisplatin dose
results in approximately half the AUC.
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scisplatin and phenoxodiol in DU145 cells may possibly be
explained by an enhanced cisplatin accumulation by phenoxodiol
in vivo. However, other mechanisms, particularly signal-transduc-
tion events, cannot be excluded. Given our promising preclinical
findings, we have initiated a phase I study of the combination of
either cisplatin or carboplatin together with phenoxodiol.
ACKNOWLEDGEMENTS
This study was funded in part by a grant provided by Novogen Pty
Ltd, Sydney, Australia. We would also like to thank Professor
Laurie Howes for helpful discussions. Dr de Souza was a consultant
for Novogen Pty Ltd in 2002.
REFERENCES
Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM (2005) Phenox-
odiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-
dependent kinase 2 activity by p53-independent induction of p21WAF1/
CIP1. Cancer Res 65: 3364–3373
Alvero AB, O’Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T,
Mor G (2006) Molecular mechanism of phenoxodiol-induced apoptosis
in ovarian carcinoma cells. Cancer 106: 599–608
Bible KC, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol
(NSC 649890, L86-8275) and various antineoplastic agents: the im-
portance of sequence of administration. Cancer Res 57: 3375–3380
Chou TC, Talalay P (1984) Quantitative analysis of dose–effect relation-
ships: the combined effects of multiple drugs or enzyme inhibitors.
Adv Enzyme Regul 22: 27–55
Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM
(2006a) Phase I trial of phenoxodiol delivered by continuous intravenous
infusion in patients with solid cancer. Ann Oncol 17: 860–865
Choueiri TK, Wesolowski R, Mekhail TM (2006b) Phenoxodiol: isoflavone
analog with antineoplastic activity. Curr Oncol Rep 8: 104–107
Constantinou AI, Husband A (2002) Phenoxodiol (2H-1-benzopyran-7-
0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA
topoisomerase II by stabilizing the cleavable complex. Anticancer Res 22:
2581–2585
Constantinou AI, Mehta R, Husband A (2003) Phenoxodiol, a novel
isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-
induced mammary carcinogenesis in female Sprague–Dawley rats.
Eur J Cancer 39: 1012–1018
de Souza PL, Castillo M, Myers CE (1997) Enhancement of paclitaxel
activity against hormone-refractory prostate cancer cells in vitro and in
vivo by quinacrine. Br J Cancer 75: 1593–1600
de Souza PL, Liauw W, Links M, Pirabhahar S, Kelly G, Howes LG (2006)
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol),
a novel isoflav-3-ene, in patients with advanced cancer. Cancer
Chemother Pharmacol 58: 427–433
Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA
(2006) Phenoxodiol, an experimental anticancer drug, shows potent
antiangiogenic properties in addition to its antitumour effects. Int J
Cancer 118: 2412–2420
Gercel-Taylor C, Feitelson AK, Taylor DD (2004) Inhibitory effect of
genistein and daidzein on ovarian cancer cell growth. Anticancer Res 24:
795–800
Hedlund TE, Johannes WU, Miller GJ (2003) Soy isoflavonoid equol
modulates the growth of benign and malignant prostatic epithelial cells
in vitro. Prostate 54: 68–78
Hempstock J, Kavanagh JP, George NJ (1998) Growth inhibition of prostate
cell lines in vitro by phyto-oestrogens. Br J Urol 82: 560–563
Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL,
Norris JS, Meyn RE, McDonnell TJ (2002) A recombinant adenovirus
expressing wild-type Bax induces apoptosis in prostate cancer cells
independently of their Bcl-2 status and androgen sensitivity. Cancer Biol
Ther 1: 163–167
Hutson T, Plavney D, Mekhail T, Dreicer R, Budd GT, Peereboom D,
Olencki T, Kelly G, Ganapathi R, Bukowski R (2003) A dose finding and
pharmacokinetic study of the novel isoflavanoid phenoxodiol in
patients with refractory malignancies. Proc Am Soc Clin Oncol 22:
Abstract 886, p 221
Hyer ML, Sudarshan S, Kim YA, Reed JC, Dong JY, Schwartz DA, Norris JS
(2002) Downregulation of c-FLIP sensitizes DU145 prostate cancer cells
to Fas-mediated apoptosis. Cancer Biol Ther 1: 401–406
Jacobsen BK, Knutsen SF, Fraser GE (1998) Does high soy milk intake
reduce prostate cancer incidence? The Adventist Health Study (United
States). Cancer Causes Control 9: 553–557
Joannou G, Kelly G, Reeder A, Waring M, Nelson C (1995) A urinary profile
study of dietary phytoestrogens. The identification and mode of
metabolism of new isoflavonoids. J Steroid Biochem Mol Biol 54:
167–184
Joshua AM, Ong S, Noney L, Millward M, Beale P, Clarke SJ, Beith J,
Kelly G, Boyer MJ (2003) Phase 1 dose-escalation study of phenoxodiol
in patients with advanced cancer. Proc Am Soc Clin Oncol 22:
Abstract 902, p 225
Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown
D, Mor G (2003) Phenoxodiol – an isoflavone analog – induces apoptosis
in chemoresistant ovarian cancer cells. Oncogene 22: 2611–2620
Kelland LR (2000) An update on satraplatin: the first orally available
platinum anticancer drug. Expert Opin Investig Drugs 9: 1373–1382
Kelly GE, Husband AJ (2003) Flavonoid compounds in the prevention and
treatment of prostate cancer. Methods Mol Med 81: 377–394
Khoshyomn S, Manske G, Lew S, Wald S, Penar P (2000) Synergistic actions
of genistein and cisplatin on growth inhibition and cytotoxicity of
human medulloblastoma cells. Pediatr Neurosurg 33: 123–131
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm
DL, Mor G (2007) The X-linked inhibitor of apoptosis protein (XIAP) is
up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxo-
diol is associated with Carboplatin sensitization. J Transl Med 5: 6
Litterst C, Magin R (1988) Alterations in plasma pharmacokinetics of
Cisplatin in tumour-bearing rats. Cancer Chemother Pharmacol 22: 1–4
Marveti G, Andrews P (1996) Stimulation of cis-diamminedochloroplati-
num(II) accumulation by modulation of passive permeability with
genistein: an altered response in accumulation defective cells.
Clin Cancer Res 2: 991–999
Mitchell JH, Duthie SJ, Collins AR (2000) Effects of phytoestrogens on
growth and DNA integrity in human prostate tumor cell lines: PC-3 and
LNCaP. Nutr Cancer 38: 223–228
Mor G, Fu HH, Alvero AB (2006) Phenoxodiol, a novel approach for the
treatment of ovarian cancer. Curr Opin Investig Drugs 7: 542–548
Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy
in the treatment of patients with hormone-refractory prostate cancer?
Cancer 109: 477–486
Phenoxodiol Investigators Brochure (2000), Vol. 4.0, pp 1–24, Novogen
Research Pty Ltd: Sydney, Australia
Petrylak DP (2007) New paradigms for advanced prostate cancer. Rev Urol
9(Suppl 2): S3–S12
Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME,
Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ,
Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared
with mitoxantrone and prednisone for advanced refractory prostate
cancer. N Engl J Med 351: 1513–1520
Risbridger G, Wang H, Frydenberg M, Husband A (2001) The in vivo effect
of red clover diet on ventral prostate growth in adult mice. Reprod Fertil
Dev 13: 325–329
Sapi E, Alvero AB, Chen W, O’Malley D, Hao XY, Dwipoyono B, Garg M,
Kamsteeg M, Rutherford T, Mor G (2004) Resistance of ovarian
carcinoma cells to docetaxel is XIAP dependent and reversible by
phenoxodiol. Oncol Res 14: 567–578
Screnci D, Galettis P, Baguely B, McKeage M (1998) Optimization of an
ICP-MS assay for the detection of trace levels of platinum in peripheral
nerves. At Spectrosc 19: 172–175
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D,
Warren J, Bokesch H, Kenney S, Boyd M (1990) New colorimetric
cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:
1107–1112
Skjoth IH, Issinger OG (2006) Profiling of signaling molecules in four
different human prostate carcinoma cell lines before and after induction
of apoptosis. Int J Oncol 28: 217–229
Straszewski-Chavez SL, Abrahams VM, Funai EF, Mor G (2004) X-linked
inhibitor of apoptosis (XIAP) confers human trophoblast cell resistance
to Fas-mediated apoptosis. Mol Hum Reprod 10: 33–41
Phenoxodiol and cisplatin in prostate cancer
RAC McPherson et al
654




















sStrom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC,
Hursting SD (1999) Phytoestrogen intake and prostate cancer: a case–
control study using a new database. Nutr Cancer 33: 20–25
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA
(2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med 351: 1502–1512
van Hennik MB, van der Vijgh WJ, Klein I, Elferink F, Vermorken JB,
Winograd B, Pinedo HM (1987) Comparative pharmacokinetics of
cisplatin and three analogues in mice and humans. Cancer Res 47:
6297–6301
Widyarini S, Spinks N, Husband A, Reeve V (2001) Isoflavanoid
compounds from red clover (Trifolium pratense) protect from inflam-
mation and suppression induced UV radiation. Photochem Photobiol 74:
465–470
Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel
B, Caligiuri M (2007) Preclinical antitumor activity of the oral platinum
analog satraplatin. Cancer Chemother Pharmacol 60: 589–600
Yagiz K, Wu LY, Kuntz CP, James Morre D, Morre DM (2006) Mouse
embryonic fibroblast cells from transgenic mice overexpressing tNOX
exhibit an altered growth and drug response phenotype. J Cell Biochem
101: 295–306
Phenoxodiol and cisplatin in prostate cancer
RAC McPherson et al
655
British Journal of Cancer (2009) 100(4), 649–655 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s